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Abstract
 
The Src homology (SH)2–containing inositol 5-phosphatase (SHIP) negatively regulates a variety
of immune responses through inhibitory immune receptors. In SHIP
 
 
 
/
 
 
 
 animals, we found
that the number of early lymphoid progenitors in the bone marrow was significantly reduced
and accompanied by expansion of myeloid cells. We exploited an in vitro system using hemato-
poietic progenitors that reproduced the in vivo phenotype of SHIP
 
 
 
/
 
 
 
 mice. Lineage-negative
marrow (Lin
 
 
 
) cells isolated from wild-type mice failed to differentiate into B cells when co-
cultured with those of SHIP
 
 
 
/
 
 
 
 mice. Furthermore, culture supernatants of SHIP
 
 
 
/
 
 
 
 Lin
 
 
 
cells suppressed the B lineage expansion of wild-type lineage-negative cells, suggesting the
presence of a suppressive cytokine. SHIP
 
 
 
/
 
 
 
 Lin
 
 
 
 cells contained more IL-6 transcripts than
wild-type Lin
 
 
 
 cells, and neutralizing anti–IL-6 antibody rescued the B lineage expansion
suppressed by the supernatants of SHIP
 
 
 
/
 
 
 
 Lin
 
 
 
 cells. Finally, we found that addition of recombi-
nant IL-6 to cultures of wild-type Lin
 
 
 
 bone marrow cells reproduced the phenotype of
SHIP
 
 
 
/
 
 
 
 bone marrow cultures: suppression of B cell development and expansion of myeloid
cells. The results identify IL-6 as an important regulatory cytokine that can suppress B lineage
differentiation and drive excessive myeloid development in bone marrow.
Key words: lymphopoiesis • inﬂammation • SHIP • interleukin 6
 
Introduction
 
Hematopoietic cells develop from a primitive stem cell
that gives rise to two precursor populations. One popula-
tion has the capacity to form myeloid and megakaryocyte
lineages (1) and is marked by low expression of IgG recep-
tors. The other population has the capacity to form all
lymphoid and natural killer cell lineages (2) and is marked
by expression of RAG. Sorted populations of lymphoid-
or myeloid-committed progenitors, defined as above,
showed minimal capacity to develop into another lineage
(1, 2). In addition to expression of RAG, lymphoid-com-
mitted precursor cells can be detected in in vitro and in
vivo assays using sorted populations that lack all lineage
markers (Lin
 
 
 
) and express the receptor for IL-7 and low
levels of surface markers Sca-1 and c-kit (IL-7R
 
 
 
, Sca-
1[low], c-kit[low]; reference 3). Expression of CD19 oc-
curs at the pro-B cell stage and corresponds to commit-
ment to the B lineage (4).
Early lymphoid-committed progenitors diverge from a
more primitive stem cell population found in the Lin
 
 
 
,
c-kit(high), Sca-1(high) population, a bone marrow fraction
which also contains precursors for myeloid lineages (5, 6).
Down-regulation of the c-kit receptor by the uncommitted
stem cell corresponds to a loss of myeloid developmental
potential and an increase in lymphoid potential (7). This is
a critical developmental decision, representing the first
commitment step from multipotent progenitors, but is the
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least understood. Information of how stem cells attenuate
self-renewal and undergo lineage commitment is essential
to appreciate the myeloid- and lymphoid-restricted devel-
opmental pathways.
Src homology (SH)2–containing 5-inositol phosphatase
(SHIP) is expressed by hematopoietic cells. SHIP is a criti-
cal negative regulator, maintaining the balance of positive
and negative signals in lymphocytes and myeloid cells (8).
Recently, an important role of SHIP in the immune system
has been manifested by establishing SHIP knockout mice.
Major features of SHIP
 
 
 
/
 
 
 
 mice include splenomegaly,
caused by hyperplasia of myeloid cells, and a massive infil-
tration of myeloid cells into lungs, causing a shortened life
span (9, 10). SHIP
 
 
 
/
 
 
 
 mice also exhibit an alteration in B
cell and myeloid numbers in the periphery and in bone
marrow progenitors. The B220
 
 
 
 B cell population is re-
duced by 
 
 
 
50% compared with wild-type littermates,
whereas myeloid cells defined by expression of Mac-1
 
 
 
 is
elevated approximately twofold in SHIP
 
 
 
/
 
 
 
 mice (9, 10).
IL-7–responsive pre-B cell precursor cells were only 
 
 
 
30%
of normal in bone marrow cells of SHIP
 
 
 
/
 
 
 
 animals (10).
In contrast, bone marrow cells were hyperresponsive upon
stimulation with cytokines that promote myeloid develop-
ment (macrophage-CSF, GM-CSF, IL-3, and Steel factor),
suggesting that the increased number of granulocyte-mac-
rophage progenitors might be explained by the hyperre-
sponsiveness to cytokines (10). This notion is supported by
reports showing that SHIP functions downstream of mac-
rophage-CSF signaling in the FDC-P1 cell line (11) and
that SHIP is involved in steel factor signaling where it neg-
atively regulates degranulation in mast cells (12–14). Poten-
tial roles for SHIP in signal transduction by the cytokines
GM-CSF and IL-3 are still unknown.
The mechanism by which SHIP affects the development
of IL-7–responsive pre-B cells and the development of ma-
ture peripheral B cells was investigated in two studies. The
first used a RAG
 
 
 
/
 
 
 
 complementation system and found
that the number of B220
 
 
 
CD43
 
 
 
 pro-B cells was normal,
but the number of B220
 
 
 
sIgM
 
 
 
 immature and B220
 
 
 
sIgD
 
 
 
mature cells were significantly reduced (15). The second
used unirradiated nonobese diabetic (NOD)/SCID animals
reconstituted with bone marrow of SHIP
 
 
 
/
 
 
 
 animals (16).
The chimeric animals exhibited a reduction of mature and
immature peripheral B cells and only a slight reduction
(30%) in total B220
 
 
 
 bone marrow cells. The authors of
both studies concluded that SHIP affects an intermediate
stage of B cell development in the transition from pro-B to
pre-B cells. The developmental defect in both cases revealed
a function of SHIP intrinsic to the B lymphoid compart-
ment, independent of the myeloproliferation defect. How-
ever, the reductions in the percentage of peripheral B cells in
the SHIP
 
 
 
/
 
 
 
 animal might be affected by the concomitant
hyperexpansion of myeloid cells present in the same mi-
croenvironment. Hence, SHIP
 
 
 
/
 
 
 
 mice may show an earlier
lymphoid lineage developmental defect that was not appar-
ent in these models, due to the absence of SHIP
 
 
 
/
 
 
 
 myeloid
cells or the absence of the myeloid hyperexpansion observed
in the SHIP-deficient animal (9, 10).
Here, we report that early B cell development is impaired
in the bone marrow of SHIP
 
 
 
/
 
 
 
 mice and confirmed the
developmental defect caused by SHIP deficiency using
serum-free, stromal cell–free cultures that support B cell
development to the pro-B cell stage. Supernatants of such
cultures of SHIP
 
 
 
/
 
 
 
 bone marrow cells when added to
wild-type cultures reproduce the defects in SHIP
 
 
 
/
 
 
 
 bone
marrow: excessive myelopoiesis and defective B cell devel-
opment. Thus, the impaired early B cell development by
SHIP deficiency is caused by suppressive soluble factors.
The soluble factor appears to be IL-6, since bone marrow–
derived Mac-1
 
 
 
 cells of SHIP
 
 
 
/
 
 
 
 animals make excessive
amounts of IL-6. Furthermore, we found that recombinant
IL-6 in stromal-free cultures of wild-type bone marrow cells
promotes myelopoiesis and suppresses B lymphoid develop-
ment. Lastly, neutralizing anti–IL-6 antibodies added to
cultures of normal marrow cells containing SHIP
 
 
 
/
 
 
 
 super-
natants rescues B lymphoid development and decreases my-
elopoiesis. Our findings reveal an important role of SHIP
and the proinflammatory cytokine IL-6 in regulating the
early stages of B lymphoid development.
 
Materials and Methods
 
Animals.
 
The SHIP
 
 
 
/
 
 
 
 mice (C57Bl/6 background) were
provided by Dr. G. Krystal. C57Bl/6 mice as wild-type controls
were purchased from The Jackson Laboratory. C57Bl/6 SJL
mice (CD45.1 background) were purchased from The Jackson
Laboratory.
 
Antibodies and Reagents.
 
Anti-CD19 mAb (1D3), anti-
CD45RA mAb (14.8), anti–Mac-1/CD11b mAb (M1/70), and
anti–IL-7R mAb (SB199) were used as described earlier (5).
Anti-SHIP mAb (P1C1) was purchased from Santa Cruz Bio-
technology and biotinylated with EZ-Link Sulfo-NHS-LC-
Biotin (Pierce Chemical Co.). Anti–IL-6 mAb (MP520F3) was
purchased from R&D Systems and used for neutralization. Anti-
TdT antibody was purchased from Supertechs. FITC-labeled
F(ab
 
 
 
)
 
2
 
 fraction of goat anti–rabbit IgG antibody was purchased
from Zymed Laboratories. All other antibodies were purchased
from BD Biosciences. Recombinant mouse IL-7, IL-6, and Flk-2
ligand were purchased from R&D Systems. Recombinant stem
cell factor was purchased from Peprotech.
 
Flow Cytometry.
 
For staining of surface antigens, cells were
incubated with combinations of labeled antibodies in PBS con-
taining 3% FCS and 5 
 
 
 
g/ml of 2.4G2 mAb (BD Biosciences).
The cells were washed and incubated with streptavidin-RED613
(Caltag) to detect biotinylated primary antibodies. For intracellu-
lar staining for TdT, cells were first stained with antibodies to
surface antigens and then fixed, permeabilized, and stained using
anti-TdT antibody FITC-labeled F(ab
 
 
 
)
 
2
 
 fraction of goat anti–
rabbit IgG antibody as described (5). For intracellular staining for
SHIP, cells were first stained with antibodies to surface antigens
and then permeabilized in PBS with 2% BSA, 2% FCS, 1 mM
EDTA, 0.2% Tween 20, and 0.01% SDS. After washing, the
cells were stained in the permeabilization buffer using anti-SHIP
mAb for 30 min at 4
 
 
 
C followed by streptavidin-RED613 for 30
min at 4
 
 
 
C. The stained cells were analyzed by FACSCalibur
and CELLQUEST software (Becton Dickinson) and FloJo soft-
ware (Treestar).
 
Isolation of Lineage-negative (Lin
 
 
 
) Cells and Cell Sorting.
 
Bone
marrow cells were isolated by flushing femurs and tibias and incu- 
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bated with unconjugated antibodies to lineage markers (Gr-1,
Mac-1, CD19, CD45R, Ter119, CD3). Bone marrow cells were
washed, incubated with goat anti–rat IgG microbeads (Miltenyi
Biotec), and applied to a magnetic separator to remove lineage-
positive cells. For further purification of Lin
 
 
 
, c-kit(high), Sca-1
 
 
 
cells, the Lin
 
 
 
 cells were incubated with FITC-conjugated anti-
bodies to lineage markers (CD3, CD8, Gr-1, Mac-1, and
CD45R), APC-conjugated anti–c-kit antibody, and PE-conju-
gated anti–Sca-1 antibody. The stained cells were subjected to
cell sorting on MoFlo (Cytomation). For purification of Mac-1
 
 
 
cells in 1-wk cultures of Lin
 
 
 
 cells, the cultured cells were stained
with FITC-conjugated anti–Mac-1 antibody and PE-conjugated
anti-CD19 antibody and sorted as described above.
 
Cell Culture.
 
The Lin
 
  
 
cells (2 
 
 
 
 10
 
4
 
) or Lin
 
 
 
, c-kit(high),
Sca-1
 
 
 
 cells (2.5 
 
 
 
 10
 
3
 
) were placed into 24-well plates in 1 ml
of X-VIVO15 medium (Biowhittaker) containing 1% detoxified
BSA (Stem Cell Technologies), 50 
 
 
 
M 
 
 
 
-mercaptoethanol, 2
mM 
 
l
 
-glutamine, 100 U/ml penicillin, 100 
 
 
 
g/ml streptomycin,
1 ng/ml IL-7, 100 ng/ml Flk-2 ligand, and 20 ng/ml stem cell
factor as described (5).
 
RNase Protection Assay.
 
Total RNA was isolated from sorted
Mac-1
 
 
 
CD19
 
 
 
 cells of 1-wk cultures of Lin
 
 
 
 cells with Mi-
croPoly(A) Pure (Ambion) according to the manufacturer’s in-
structions. 5 
 
 
 
g of polyA-containing RNA was hybridized with
 
32
 
P-labeled riboprobes provided by Multi-Probe RNase Protec-
tion Assay System mCK-3b (BD Biosciences). The hybrid
mRNA were digested with RNase A 
 
 
 
 T1 mix and separated on
acrylamide gel electrophoresis according to the manufacturer’s in-
struction. The dried acrylamide gel was exposed to x-ray film or
applied to a Molecular Dynamics Storm system.
 
RT-PCR.
 
Total RNAs were reverse transcribed to cDNAs
using SuperScript II reverse transcriptase (Invitrogen). Primer
pairs for mouse TNF
 
 
 
, IL-6, IL-1
 
 
 
, 
 
 
 
-actin were obtained from
Biosource. Primers for mouse LT
 
 
 
 was designed as described in
Weih et al. (17). The PCR was performed at 25–30 cycles as fol-
lows: 1 min at 94
 
 
 
C, 1 min at 55
 
 
 
C, and 1 min at 72
 
 
 
C. PCR
products were not saturated under these conditions. PCR prod-
ucts were visualized and quantified by LumiImager (Roche).
 
Results
 
Early Stage of B Cell Development Is Impaired in the Bone
Marrow of SHIP
 
 
 
/
 
 
 
 Mice.
 
To investigate the role of SHIP
at early stages of B lymphoid development, we examined
lymphoid progenitors and immature B cells in the bone
marrow of SHIP
 
 
 
/
 
  mice compared with the wild-type lit-
termates by flow cytometry. The results of FACS® profiles
are shown in Fig. 1. Total cell numbers for the populations
in the bone marrow examined are also shown in Table I. As
reported previously (16), the total B cell population, defined
by the surface expression of CD19, was reduced in total
bone marrow cells in SHIP /  mice, whereas the popula-
tion of myeloid cells, defined by the surface expression of
Mac-1 was increased (Fig. 1 A and Table I). We found that
the number of CD19  cells declines with increasing age
(Fig. 1 A and unpublished data). In SHIP /  mice, we ob-
served that pro-B cell population defined earlier (18) as
CD43 B220  was reduced to  50% relative to wild-type
mice, although it was reported that pro-B cell number is
normal in SHIP /  bone marrow (16). Further investiga-
tion of the earlier stage of B lymphoid development dem-
onstrated that the number of Lin , c-kit(low), IL-7R  
cells in SHIP /  mice was also decreased to 30% of the
wild-type level. Additionally, prolymphocytes defined pre-
viously (19) as Lin , c-kit(low), IL-7R  , Flk-2  cells
were also reduced to 30% of normal in SHIP /  mice. This
prolymphocyte population overlaps to a large extent with
common lymphoid progenitors defined by others on the
basis of slightly different characteristics (3, 20).
Table I. Populations on Early Lymphocyte Precursors, B Lymphocytes, and Myeloid Cells in SHIP /  Bone Marrow Cells
Percentage Cell number
SHIP /  bone marrow cells SHIP /  SHIP /  SHIP /  SHIP / 
CD19  28   11 7.5   5.3a 16   8 ( 106) 3.4   2.7 ( 106)a
Mac-1  30   6 54   12a 18   7 ( 106) 24   10 ( 106)b
CD43 B220  6.2   1.6 4.2   1.1b 3.8   0.8 ( 106) 1.8   0.7 ( 106)a
CD43 B220(low) 24   7 5.2   4.4a 16   6 ( 106) 0.6   0.2 ( 106)a
CD43 B220(high) 6.0   0.8 2.4   2.0a 3.8   0.8 ( 106) 0.7   0.6 ( 106)a
Lin  1.4   0.6 2.2   1.3b 8.1   2.3 ( 105) 9.1   4.0 ( 105)
Lin , c-kit(low), IL-7R   0.13   0.09 0.06   0.04b 8.7   6.3 ( 104) 2.5   1.9 ( 104)b
Lin , c-kit(low), 
IL-7R  , Flk-2  0.09   0.05 0.04   0.03b 5.8   3.3 ( 104) 1.8   1.4 ( 104)b
Lin , c-kit(high), Sca-1  0.08   0.03 0.14   0.08b 4.9   2.5 ( 104) 7.7   5.7 ( 104)b
Lin , c-kit(high), Sca-1 , 
CD27 , TdT  0.024   0.002 0.022   0.012 1.55   0.10 ( 104) 1.29   0.30 ( 104)
Total bone marrow cells or Lin  cells were labeled with the indicated antibodies and analyzed by FACS®. The data were obtained from at least three
2–5-wk-old mice and are shown as averages. Cell numbers are shown as the number per mouse (two femurs and two tibias). Value is different from
control SHIP /  with a significance of aP   0.001 and bP   0.05 by Student’s t test.IL-6 Production by SHIP /  Myeloid Cells Suppresses Lymphoid Development 246
Even more primitive lymphocyte progenitors have been
identified within a small Lin  c-kit(high), Sca-1  CD27 
fraction of bone marrow according to hormone sensitivity,
TdT expression, synthesis of an immunoglobulin trans-
gene, and activation of the RAG-1 locus (2, 6). These early
lymphoid progenitors are not homogeneous, do not yet
express transcripts for Pax-5 or IL-7R , and take longer to
generate CD19  cells than prolymphocytes. In the present
study, we enumerated Lin , c-kit(high), Sca-1 , CD27 ,
TdT  progenitors in SHIP /  and wild-type bone marrow
by flow cytometry (Fig. 1 B). Although percentages in
SHIP /  mice were significantly lower than in wild-type
mice (12 versus 33%, respectively), absolute numbers of
these fractions were not significantly different (Fig. 1 B and
Table I). Hence, our findings show that SHIP regulates an
additional and previously unappreciated transition stage—
that of early lymphoid progenitors to prolymphocytes. Our
observations that more primitive lymphoid precursors are
affected in the SHIP /  animal is in contrast to studies us-
ing models of RAG /  complementation (15) or unirradi-
Figure 1. Flow cytometric analysis of bone marrow cells
in SHIP /  and SHIP /  mice. Total bone marrow cells
(A) or sorted Lin  cells (B) were isolated from 2–5-wk-old
SHIP /  and SHIP /  mice. The staining protocol is
described in Materials and Methods. Numbers represent
the percentage of cells within each marked region. Results
are representative of at least three independent experiments.Nakamura et al. 247
ated NOD/SCID (16) mice, where the contributions to
lymphoid development by the SHIP-deficient myeloid
cells were removed or diminished.
In B cells, SHIP function requires expression and B cell
receptor coclustering of Fc  receptor II  (Fc RII) (21).
However, we found no abnormality at any developmental
stages in bone marrow of Fc RII /  mice (Fig. 1, A and
B). These observations indicate that SHIP functions inde-
pendently of Fc RII to regulate B cell development in
bone marrow. This function of SHIP is distinct from that
used in mature B cells.
We then exploited serum-free, stromal cell-free cultures
using Lin  cells or Lin , c-kit(high), Sca-1  cells as start-
ing materials. In this culture system, B cell development is
supported to the pro-B and pre-B cell stage because
CD19  cells in the Lin  culture after 1 wk still express
CD43 (5; unpublished data). Therefore, serum-free, stro-
mal cell–free cultures provide a useful way to analyze early
stages of lymphoid development. Using this model, we
found in both cultures of Lin  cells and Lin , c-kit(high),
Sca-1  cells that the number of CD19  cells were 20-
(Lin ) or 10- (Lin , c-kit[high], Sca-1 ) fold smaller than
Figure 2. Cultures of Lin  or Lin , c-kit(high), Sca-1  cells of SHIP / 
and SHIP /  mice. (A) Purified Lin  (top) or Lin-, c-kit(high), Sca-1 
(bottom) cells from SHIP /  (left) or SHIP /  (right) mice were incu-
bated for 1 (Lin ) or 2 wk (Lin , c-kit[high], Sca-1 ) in serum-free, stromal
cell–free cultures. The CD19  and Mac-1  cells were analyzed by
FACS® after culture. Numbers represent the percentage of cells within
each marked region. (B) The absolute numbers of CD19  and Mac-1 
cells in A were shown as the average of triplicate wells of six independent
experiments for Lin  cells or three experiments for Lin , c-kit(high), Sca-1 
cells. Student’s t test (*) was used to assess statistical significance of the
difference between CD19  and Mac-1  cells of the wild-type and
SHIP /  cultures.
Figure 3. Expression of SHIP in subsets of bone marrow cells. Spleno-
cytes (A and B), total bone marrow cells (C–E), and Lin  cells (F–H)
were stained with the indicated antibodies and then permeabilized and
stained with anti-SHIP monoclonal antibody. Solid lines and dashed lines
indicate the cells from SHIP /  and control staining of SHIP /  mice,
respectively.IL-6 Production by SHIP /  Myeloid Cells Suppresses Lymphoid Development 248
those of wild-type (Fig. 2). The number of Mac-1  cells
was twofold larger in Lin  culture. These results clearly
demonstrated that SHIP deficiency alters early stages of B
lymphoid development.
Expression of SHIP in Bone Marrow. Our findings indi-
cating that the lack of the SHIP gene affects early B lym-
phoid and myeloid development predicted that SHIP is
expressed in the precursor cell populations. To test this
prediction, we stained marrow cells with markers defining
lineage stages and performed intracellular staining of SHIP
using a commercial monoclonal antibody. The stained
cells were then analyzed by flow cytometry. The results
shown in Fig. 3 indicate that SHIP is expressed in hemato-
poietic stem cell–enriched faction (Fig. 3 G), common
myeloid progenitors (Fig. 3 H), prolymphocytes (Fig. 3 F),
pro-B and large pre-B cells (Fig. 3 D), small pre-B cells
(Fig. 3 E), and immature B cells in bone marrow (Fig. 3
C). Splenic B cells also expressed SHIP, whereas splenic
erythrocytes showed only background staining (Fig. 3, A
and B, respectively). These data indicate that SHIP is
widely expressed in bone marrow subpopulations and
therefore is capable of functioning at all stages of lymphoid
and myeloid development.
Soluble Factor(s) Produced by the Cells Derived from SHIP / 
Mice Suppress B Cell Development In Vitro. There are
two possibilities to explain the impairment in B lymphoid
development in SHIP /  mice. First, SHIP may intrinsi-
cally regulate the early stages of all lymphoid development
in progenitor cells. Thus, expression of SHIP is required
for the maturation of cells within the lymphoid compart-
ment. Second, development of lymphoid precursors in
SHIP /  mice may be blocked by extrinsic factors, includ-
ing a bystander effect caused by the presence of other cell
types. These possibilities are not mutually exclusive. To
test these possibilities, we established cocultures in which
wild-type Lin  cells derived from C57Bl/6 SJL mice
(CD45.1 background) were cultured together with the
same number of Lin  cells from either SHIP /  or
SHIP /  mice. The cells expressing CD45.1 and origi-
nating from C57Bl/6 SJL mice could be distinguished
from the SHIP / - or SHIP / -derived cells expressing
CD45.2 by flow cytometry. The results of the coculture
are shown in Fig. 4. The data clearly show that the total
number and percentage of CD45.1 CD19  cells derived
from Lin  cells of C57Bl/6 SJL mice were decreased
when cocultured with SHIP /  Lin  cells, whereas
CD45.1 CD19  cells cocultured with SHIP /  Lin  cells
developed normally. In contrast with CD19  cells,
CD45.1 Mac-1  cells were elevated threefold when co-
cultured with SHIP /  Lin  cells. Thus, the ability of
progenitors to develop into lymphoid-committed cells is
suppressed when SHIP /  marrow cells are present. Es-
sentially the same results were obtained when Lin , c-kit(high),
Sca-1  cells were used (Fig. 4 B). Hence, the presence
of myeloid cells in the SHIP /  culture appears to affect
B lineage development. The results are consistent with
the hypothesis that the myeloid hyperplasia in SHIP / 
animals could contribute to the loss of lymphoid precur-
sors.
To examine whether the cells derived from the SHIP / 
culture suppress B cell development by cell–cell contact or
by production of soluble factor(s), we cultured Lin  cells
from wild-type mice with supernatants of the SHIP / 
Figure 4. Cocultures of SHIP /  or SHIP /  Lin  cells with wild-type
Lin  cells. Lin  cells from SHIP /  or SHIP /  mice were cocultured in
vitro with Lin  cells from wild-type mice for 1 wk, and then
CD19 CD45.1  or CD19 CD45.2  cells were analyzed by FACS®.
The cells derived from wild-type mice were distinguished by staining
with anti-CD45.1 antibody from those of SHIP /  or SHIP /  mice,
expressing CD45.2. Numbers represent the percentage of cells within
each marked region. (B) The absolute numbers of CD19  and Mac-1 
cells in A were shown as the averages of triplicate wells and are represen-
tative of two independent experiments. Student’s t test (*) was used to
assess statistical significance of the difference between CD19 CD45.1/2 
and Mac-1 CD45.1/2  cells derived from cultures containing SHIP / 
and/or SHIP /  cells.Nakamura et al. 249
culture, and the number of CD19  and Mac-1  cells was
determined. We found that the culture supernatant of
SHIP /  Lin  cells reduced the total number and percent-
age of CD19  cells to 30% of the control, whereas that of
SHIP /  Lin  cells had only a small effect (Fig. 5). In par-
allel, total Mac-1  cells were  10-fold increased when the
culture supernatant of SHIP / , Lin  cells were added.
These results demonstrated that soluble factor(s) produced
by SHIP /  bone marrow cells are capable of suppress-
ing B lymphoid and enhancing myeloid development in
SHIP /  culture.
IL-6 Is Overproduced by Myeloid Cells in SHIP /  Culture
and Is a Candidate Cytokine for the Suppression of B Cell De-
velopment and Expansion of Myeloid Cells in SHIP /  Mice.
To identify the soluble factor(s) which suppresses the
early stages of B cell development and increases the num-
ber of myeloid cells, we performed RNase protection assay
and RT-PCR analyses. Mac-1  cells in 1-wk culture of
SHIP /  Lin  cells were sorted and subjected to RNase
protection assay and RT-PCR. The results of RNase pro-
tection assay and the quantified data are shown in Fig. 6, A
and B. The data revealed that only IL-6 mRNA was sig-
nificantly up-regulated in SHIP /  Mac-1  cells among
nine different cytokines examined. The level of IL-6
mRNA expression was fivefold higher than that of wild-
type Mac-1  cells. To confirm the results of RNase pro-
tection assay, we performed semiquantitative RT-PCR to
detect inflammatory cytokines TNF , LT , IL-1 ,  and
IL-6. Consistent with the results of RNase protection as-
say, the level of TNF , LT , and IL-1  were essentially
identical between SHIP /  and wild-type Mac-1  cells,
whereas IL-6 mRNA was 3.5-fold increased relative to
wild-type (Fig. 6, C and D). These results indicate that
IL-6 is a possible suppressor of B lymphoid development in
SHIP /  mice.
To test whether IL-6 is capable of suppressing B lym-
phoid and enhancing myeloid development, we added
neutralizing antibody to IL-6 to cultures of wild-type Lin 
cells in the presence of SHIP /  culture supernatants. We
found that the reduced number of CD19  cells in the
wild-type Lin  culture in the presence of the SHIP /  cul-
ture supernatant was restored to control levels by the addi-
tion of neutralizing anti–IL-6 antibodies (Fig. 7 A). There
was no effect of anti–IL-6 antibody on B cell development
in wild-type culture in the presence of SHIP /  culture su-
pernatant or on cultures lacking culture supernatants. The
enhancing effect of the SHIP /  culture supernatant on the
total number of Mac-1  cells in the culture was also re-
versed by the addition of anti–IL-6 antibody (Fig. 7 A).
There was no significant effect on myeloid development
when the anti–IL-6 antibody was added to the culture of
wild-type Lin  cells in the presence or absence of culture
supernatants of wild-type Lin  cells.
To confirm that IL-6 has the potential to regulate the
balance of lymphopoiesis and myelopoiesis in vitro, we ex-
amined the effect of recombinant IL-6 on B lymphoid de-
velopment and myeloid development in wild-type Lin 
cell cultures. Recombinant IL-6 reduced the number of
CD19  cells in 1-wk cultures in a dose-dependent manner
(Fig. 7 B). In contrast, the number of Mac-1  cells was
fivefold increased at 10 ng/ml of recombinant IL-6 (Fig. 7
B). Together, these findings show that IL-6 is a potential
candidate cytokine that can account for the observed re-
pression of lymphoid and expansion of myeloid develop-
ment in SHIP /  animals.
Figure 5. Effects of culture supernatants of SHIP /  Lin  cells on the
cultures of wild-type Lin  cells. 2   104 Lin  cells from SHIP /  (A, C,
and D) or SHIP /  (B) mice were cultured for 1 wk in the absence (A
and B) or presence (C and D) of culture supernatants (Sup) from 1-wk
cultures of SHIP /  (C) or SHIP /  (D) Lin  cells. Supernatants were
used at a concentration of 30% vol/vol. The CD19  and Mac-1  cells
were analyzed by FACS®. Numbers represent the percentage of cells
within each marked region. (B) The absolute numbers of CD19  and
Mac-1  cells in A were shown as the averages of triplicate wells and are
representative of two independent experiments. Student’s t test (*) was
used to assess statistical significance of the difference between cultures
containing SHIP /  or SHIP /  supernatant.IL-6 Production by SHIP /  Myeloid Cells Suppresses Lymphoid Development 250
In Fig. 1 A, we showed that the number of CD19  cells
declines with increasing age of SHIP /  mice. The age ef-
fect may be due to a lack of IL-6 sensitivity of fetal lym-
phoid precursors. To test this possibility, we examined the
ability of recombinant IL-6 to suppress lymphoid develop-
ment of Lin  cells derived from fetal liver. We found that
production of B lymphoid precursors in cultures of Lin 
fetal liver cells of both wild-type and SHIP /  were
equally sensitive to exogenous IL-6 (unpublished data).
Thus, the age effect is not due to a lack of IL-6 sensitivity
in fetal liver-derived precursors. One possible explanation
is that the SHIP /  mice need to accumulate sufficient
Mac-1  cells and IL-6 levels before the affect on lymphoid
development is apparent.
Discussion
SHIP /  animals exhibit a reduction in mature periph-
eral B cells and increases in myeloid cell number (9, 10).
Previous experiments identified a defect in the transition
from pro-B to pre-B cell stage (15, 16). No defect in the
development of primitive lymphoid progenitors was ap-
parent from these experiments. However, those studies
used models in which contributions to lymphoid develop-
ment by the myeloid fraction of SHIP /  bone marrow
were minimized by complementation of RAG /  blasto-
cysts or the use of unirradiated NOD/SCID mice. We
demonstrate here the important contributions of SHIP and
of the myeloid expansion in SHIP /  mice toward the
early stages of lymphoid development in bone marrow.
Our results further identified an important role of IL-6 in
affecting lymphoid and myeloid cell development. In bone
marrow of SHIP /  animals, we found dramatic alter-
ations in populations pro-lymphocytes (Lin , c-kit[low],
IL-7R , Flk-2 ) and pro-B cells (CD43 B220 ). Lastly,
we found that deficiencies in early lymphoid development
are associated at least in part with overproduction of IL-6
secreted by Mac-1  myeloid cells. The suppression of
lymphoid progenitors in the SHIP-deficient mouse is un-
likely to involve lineage choice decisions, since equal total
numbers of Lin  c-kit(high) Sca-1  CD27  TdT  cells
were present in wild-type and SHIP /  mice. Recent
studies revealed that while these early lymphoid progeni-
tors are very primitive, they have little potential for non-
lymphoid lineage differentiation (2, 6). Thus, our findings
strongly support our current hypothesis that SHIP expres-
sion affects expansion and/or survival of lymphoid-com-
mitted progenitors.
Figure 6. IL-6 mRNA levels are increased in SHIP / 
Mac-1  cells. (A). Cytokine mRNAs were analyzed by
RNase protection assay using total RNAs from Mac-1 
cells isolated from 1-wk culture of SHIP /  or SHIP / 
Lin  cells. Results from 1-d exposure (left) and 1-wk ex-
posure (right) are shown. The positions of protected frag-
ments corresponding to the mRNAs of cytokines were
indicated on the right. (B). The amount of mRNA of each
cytokine to L32/GAPDH shown in A was quantified. The
amounts in the SHIP /  cells are shown as values relative
to those of SHIP /  cells. (C). The mRNAs for TNF ,
IL-6, IL-1 , and LT  were analyzed by RT-PCR using
the total RNAs described in A. The PCR products with-
out reverse transcription are shown as negative controls
(RT ). (D). The amount of mRNA of each cytokine to
 -actin shown in C was quantified and shown as relative
values to those of SHIP /  cells.Nakamura et al. 251
Our findings are consistent with the 70% reduction in
IL-7–responsive precursor cells in bone marrow of SHIP-
deficient mice (10) but appeared at first to contradict earlier
reports showing that the number of B220 CD43  pro-B
cells was normal in SHIP / , RAG /  (15) or SHIP / ,
NOD–SCID chimeras (16). In the SHIP / RAG /  chi-
meric mice, all lymphocytes were derived from SHIP / 
embryonic stem cells, but myeloid cells were generated
from both SHIP /  embryonic stem cells and RAG / 
blastocysts. Similarly, the NOD–SCID study used animals
that had not been irradiated, thereby retaining host my-
eloid cells. The few myeloid cells derived from bone mar-
row of SHIP /  mice in the NOD–SCID chimeras may
have been unable to produce sufficient IL-6 to suppress
early B cell development, or myeloid cells from SHIP / 
progenitors may have failed to differentiate. Indeed, the
Mac-1 ,Gr-1  population from SHIP /  donors did not
expand in the unirradiated NOD/SCID model (16). It is
not clear why we found a decrease in pro-B cells (Fig. 1 A
and Table I) in SHIP /  bone marrow, whereas an early
study using the same SHIP /  animals found normal levels
of pro-B cells (16). One possibility is that the SHIP /  ani-
mals used earlier were F2 or F3 generation of backcrossing
with C57Bl/6. At F2/3, the chimeras still have a consider-
able contribution from the strain 129 mouse genome. We
received the animals after an additional 1 yr of backcrossing
to C57Bl/6, although the precise number of backcrossings
could not be determined. In any case, the results reported
here used a strain that is well beyond F2/F3. The myeloid
phenotype becomes more severe with backcrossing to
C57Bl/6 (Krystal, G., personal communication), and the
affect on lymphoid development appears to be due to my-
eloexpansion in SHIP / . Therefore, the difference be-
tween these findings and the earlier reports is likely due to
a greater genetic contribution from C57Bl/6 in the SHIP / 
strain tested here.
It is not clear why the phenotype worsens with age. We
found that fetal liver cells of both wild-type and SHIP / -
derived precursors were equally sensitive to added IL-6.
One possibility is that IL-6 levels in utero or in young ani-
mals are not present at sufficient levels to suppress B lym-
phoid development. Since the origin of the elevated IL-6 is
through myeloid cells in the SHIP /  animal, it may be
that the myeloid cells have not accumulated in fetal or
neonatal mice.
IL-6 is a cytokine produced during inflammation (for re-
view see reference 22). Knockout studies indicate that the
IL-6 receptor is required for terminal differentiation of my-
eloid cells but not for formation of myeloid precursors (23).
Administration of IL-6 to irradiated transplant patients (24)
or animals (25) accelerates recovery of myeloid cells. Thus,
IL-6 supports myeloid development and function in vivo.
Furthermore, deregulation of IL-6 production is implicated
in the pathology of several disease processes. IL-6 supports
the growth of myelomas (26), and IL-6 transgenic mice de-
velop a fatal plasmacytosis (27). Consistent with an effect of
IL-6 on mature lymphocytes, animals expressing high IL-6
levels show increased peripheral mature lymphocytes (28,
29) and the development of lymph node-like structures at
sites of IL-6 production (30). It is possible that the mature
B cells of SHIP /  animals might recover from the reduced
output of lymphoid progenitors by overproduction of IL-6
in peripheral organs. Indeed, total B cell number in SHIP / 
spleens seems to be normal (10, 16; unpublished data).
Increased IL-6 levels are found in several autoimmune dis-
Figure 7. IL-6 suppresses B lymphoid and enhances myeloid develop-
ment. (A) Lin  cells of wild-type C57Bl/6 mice were cultured with the
combination of anti–IL-6 antibody and culture supernatants (30% in volume)
of 1-wk cultures of SHIP /  or SHIP /  Lin  cells as indicated. Numbers of
CD19  cells (white bars) and Mac-1  cells (black bars) are shown as averages
of triplicate wells and represent two independent experiments. (B) Lin 
cells of wild-type mice were cultured for 1 wk with different concentrations
of recombinant IL-6 as indicated. Numbers of CD19  ( ) and Mac-1 
( ) cells were shown as averages of duplicate wells. Bars represent SDs of
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eases (for review see reference 22), including rheumatoid
arthritis (31). Accordingly, neutralizing IL-6 reagents have
proven effective therapies for autoimmune diseases (32,
33). Lastly, transgenic animals harboring a Y to F point
mutant IL-6 receptor spontaneously develop rheumatoid
arthritis (34). Thus, unregulated IL-6 signaling or produc-
tion promotes autoimmune disease.
There is little information on the role or the effects of
IL-6 in the formation or survival of early lymphoid and
myeloid progenitors. Our data identified a novel function
of IL-6 to inhibit early lymphoid development and acceler-
ate myeloid development. Other cytokines associated with
inflammation such as IL-1 (35), IFN (36), TNF (37), and
TGF-  (38) produce a phenotype similar to our observa-
tions of SHIP /  animals: suppression of lymphoid but not
myeloid precursor growth or survival. Furthermore,
chronic inflammation caused by various autoimmune dis-
eases promotes a lymphopenic state (39–41). The mecha-
nism of lymphopenia that accompanies autoimmunity is
unclear, but the observation is consistent with the findings
reported here. Thus, inflammation may block development
of lymphoid precursors and result in lymphopenia. Similar
defects in lymphoid development (42) or lymphopenia (43,
44) are associated in patients with IL-6–dependent multiple
myeloma or with graft versus host disease (45). Despite the
lack of direct information on lymphopoiesis, the clinical
data on IL-6 and the animal models of IL-6 transgenics and
knockouts suggest that IL-6 plays an important but unap-
preciated role in lymphopoiesis.
Although we found elevated IL-6 production in SHIP / 
Mac-1  cells, it is still unclear whether SHIP directly
regulates IL-6 production in myeloid cells. IL-6 production
is induced by IL-1 and by LPS in macrophages, but the
possible involvement of SHIP in those signaling pathways
has not been studied. Others have shown a marked increase
of serum IL-6 levels in SHIP /  mice (46). Observations
that IL-6 is up-regulated in mast cells derived from SHIP / 
mice supports our finding in Mac-1  cells of the same
animal (47). NF- B is a major transcription factor that reg-
ulates IL-6 production. It was reported that NF- B activa-
tion is blocked by the overexpression of SHIP in macro-
phages stimulated with anti–Fc receptor antibodies (48).
The role of SHIP in NF- B signaling pathways remains to
be elucidated.
SHIP is thought to function by opposing the activation
effects of phosphatidylinositol 3-kinase (PI-3K) through
the hydrolysis of its lipid product, phosphatidylinositol
3,4,5-trisphosphate (PIP3). Mice deficient in the p85  reg-
ulatory subunit of PI-3K exhibit a mild Xid-like phenotype
and a significant increase in pro-B cell (B220 CD43 )
population in the bone marrow (49, 50). Together with
our findings, these data show that an early stage of lym-
phoid and myeloid development in marrow is tightly regu-
lated by PIP3 production through PI-3K and PIP3 hydro-
lysis through SHIP.
We thank Gerry Krystal (British Columbia Cancer Agency, Van-
couver, B.C., Canada) for providing SHIP /  mice.
M. Coggeshall is supported by National Institutes of Health
grants AI49264, CA64268, and RR015577. Dr. Coggeshall is a
Scholar of the Leukemia and Lymphoma Society.
Submitted: 17 July 2003
Accepted: 2 December 2003
References
1. Akashi, K., D. Traver, T. Miyamoto, and I.L. Weissman.
2000. A clonogenic common myeloid progenitor that gives
rise to all myeloid lineages. Nature. 404:193–197.
2. Igarashi, H., S.C. Gregory, T. Yokota, N. Sakaguchi, and
P.W. Kincade. 2002. Transcription from the RAG1 locus
marks the earliest lymphocyte progenitors in bone marrow.
Immunity. 17:117–130.
3. Kondo, M., I.L. Weissman, and K. Akashi. 1997. Identifica-
tion of clonogenic common lymphoid progenitors in mouse
bone marrow. Cell. 91:661–672.
4. Rolink, A., E. ten Boekel, F. Melchers, D.T. Fearon, I.
Krop, and J. Andersson. 1996. A subpopulation of B220 
cells in murine bone marrow does not express CD19 and
contains natural killer cell progenitors. J. Exp. Med. 183:187–
194.
5. Kouro, T., K.L. Medina, K. Oritani, and P.W. Kincade.
2001. Characteristics of early murine B-lymphocyte precur-
sors and their direct sensitivity to negative regulators. Blood.
97:2708–2715.
6. Medina, K.L., K.P. Garrett, L.F. Thompson, M.I. Rossi, K.J.
Payne, and P.W. Kincade. 2001. Identification of very early
lymphoid precursors in bone marrow and their regulation by
estrogen. Nat. Immunol. 2:718–724.
7. Payne, K.J., K.L. Medina, and P.W. Kincade. 1999. Loss of
c-kit accompanies B-lineage commitment and acquisition of
CD45R by most murine B-lymphocyte precursors. Blood.
94:713–723.
8. Nakamura, K., A. Malykhin, and K.M. Coggeshall. 2002.
The Src homology 2 domain-containing inositol 5-phos-
phatase negatively regulates Fcgamma receptor-mediated
phagocytosis through immunoreceptor tyrosine-based activa-
tion motif-bearing phagocytic receptors. Blood. 100:3374–
3382.
9. Liu, Q., T. Sasaki, I. Kozieradzki, A. Wakeham, A. Itie, D.J.
Dumont, and J.M. Penninger. 1999. SHIP is a negative regu-
lator of growth factor receptor-mediated PKB/Akt activation
and myeloid cell survival. Genes Dev. 13:786–791.
10. Helgason, C.D., J.E. Damen, P. Rosten, R. Grewal, P. So-
rensen, S.M. Chappel, A. Borowski, F. Jirik, G. Krystal, and
R.K. Humphries. 1998. Targeted disruption of SHIP leads to
hemopoietic perturbations, lung pathology, and a shortened
life span. Genes Dev. 12:1610–1620.
11. Liu, Y., B. Jenkins, J.L. Shin, and L.R. Rohrschneider. 2001.
Scaffolding protein Gab2 mediates differentiation signaling
downstream of Fms receptor tyrosine kinase. Mol. Cell. Biol.
21:3047–3056.
12. Huber, M., C.D. Helgason, M.P. Scheid, V. Duronio, R.K.
Humphries, and G. Krystal. 1998. Targeted disruption of
SHIP leads to Steel factor-induced degranulation of mast
cells. EMBO J. 17:7311–7319.
13. Huber, M., C.D. Helgason, J.E. Damen, L. Liu, R.K.
Humphries, and G. Krystal. 1998. The src homology 2-con-
taining inositol phosphatase (SHIP) is the gatekeeper of mast
cell degranulation. Proc. Natl. Acad. Sci. USA. 95:11330–Nakamura et al. 253
11335.
14. Damen, J.E., M.D. Ware, J. Kalesnikoff, M.R. Hughes, and
G. Krystal. 2001. SHIP’s C-terminus is essential for its hydro-
lysis of PIP3 and inhibition of mast cell degranulation. Blood.
97:1343–1351.
15. Liu, Q., A.J. Oliveira-Dos-Santos, S. Mariathasan, D. Bou-
chard, J. Jones, R. Sarao, I. Kozieradzki, P.S. Ohashi, J.M.
Penninger, and D.J. Dumont. 1998. The inositol polyphos-
phate 5-phosphatase ship is a crucial negative regulator of B
cell antigen receptor signaling. J. Exp. Med. 188:1333–1342.
16. Helgason, C.D., C.P. Kalberer, J.E. Damen, S.M. Chappel,
N. Pineault, G. Krystal, and R.K. Humphries. 2000. A dual
role for Src homology 2 domain–containing inositol-5-phos-
phatase (SHIP) in immunity: aberrant development and en-
hanced function of B lymphocytes in SHIP /  mice. J. Exp.
Med. 191:781–794.
17. Weih, D.S., Z.B. Yilmaz, and F. Weih. 2001. Essential role
of RelB in germinal center and marginal zone formation and
proper expression of homing chemokines. J. Immunol. 167:
1909–1919.
18. Hardy, R.R., C.E. Carmack, S.A. Shinton, J.D. Kemp, and
K. Hayakawa. 1991. Resolution and characterization of
pro-B and pre-pro-B cell stages in normal mouse bone mar-
row. J. Exp. Med. 173:1213–1225.
19. Tudor, K.S., K.J. Payne, Y. Yamashita, and P.W. Kincade.
2000. Functional assessment of precursors from murine bone
marrow suggests a sequence of early B lineage differentiation
events. Immunity. 12:335–345.
20. Allman, D., J. Li, and R.R. Hardy. 1999. Commitment to
the B lymphoid lineage occurs before DH-JH recombina-
tion. J. Exp. Med. 189:735–740.
21. Tridandapani, S., T. Kelley, M. Pradhan, D. Cooney, L.B.
Justement, and K.M. Coggeshall. 1997. Recruitment and
phosphorylation of SHIP and Shc to the B cell Fcgamma
ITIM peptide motif. Mol. Cell. Biol. 17:4305–4311.
22. Ishihara, K., and T. Hirano. 2002. IL-6 in autoimmune dis-
ease and chronic inflammatory proliferative disease. Cytokine
Growth Factor Rev. 13:357–368.
23. Liu, F., J. Poursine-Laurent, H.Y. Wu, and D.C. Link. 1997.
Interleukin-6 and the granulocyte colony-stimulating factor
receptor are major independent regulators of granulopoiesis
in vivo but are not required for lineage commitment or ter-
minal differentiation. Blood. 90:2583–2590.
24. Patchen, M.L., T.J. MacVittie, J.L. Williams, G.N. Schwartz,
and L.M. Souza. 1991. Administration of interleukin-6 stim-
ulates multilineage hematopoiesis and accelerates recovery
from radiation-induced hematopoietic depression. Blood. 77:
472–480.
25. Serrano, F., F. Varas, A. Bernad, and J.A. Bueren. 1994. Ac-
celerated and long-term hematopoietic engraftment in mice
transplanted with ex vivo expanded bone marrow. Bone Mar-
row Transplant. 14:855–862.
26. Nilsson, K., H. Jernberg, and M. Pettersson. 1990. IL-6 as a
growth factor for human multiple myeloma cells—a short
overview. Curr. Top. Microbiol. Immunol. 166:3–12.
27. Suematsu, S., T. Matsuda, K. Aozasa, S. Akira, N. Nakano,
S. Ohno, J. Miyazaki, K. Yamamura, T. Hirano, and T.
Kishimoto. 1989. IgG1 plasmacytosis in interleukin 6 trans-
genic mice. Proc. Natl. Acad. Sci. USA. 86:7547–7551.
28. Braciak, T.A., S.K. Mittal, F.L. Graham, C.D. Richards, and
J. Gauldie. 1993. Construction of recombinant human type 5
adenoviruses expressing rodent IL-6 genes. An approach to
investigate in vivo cytokine function. J. Immunol. 151:5145–
5153.
29. Puri, R.K., and P. Leland. 1992. Systemic administration of
recombinant interleukin-6 in mice induces proliferation of
lymphoid cells in vivo. Lymphokine Cytokine Res. 11:133–
139.
30. Goya, S., H. Matsuoka, M. Mori, H. Morishita, H. Kida, Y.
Kobashi, T. Kato, Y. Taguchi, T. Osaki, I. Tachibana, et al.
2003. Sustained interleukin-6 signalling leads to the develop-
ment of lymphoid organ-like structures in the lung. J. Pathol.
200:82–87.
31. Miyazawa, K., A. Mori, and H. Okudaira. 1999. IL-6 synthe-
sis by rheumatoid synoviocytes is autonomously upregulated
at the transcriptional level. J. Allergy Clin. Immunol. 103:
S437–S444.
32. Yoshizaki, K., N. Nishimoto, M. Mihara, and T. Kishimoto.
1998. Therapy of rheumatoid arthritis by blocking IL-6 signal
transduction with a humanized anti-IL-6 receptor antibody.
Springer Semin. Immunopathol. 20:247–259.
33. Mihara, M., M. Kotoh, N. Nishimoto, Y. Oda, E. Kumagai,
N. Takagi, K. Tsunemi, Y. Ohsugi, T. Kishimoto, K.
Yoshizaki, and Y. Takeda. 2001. Humanized antibody to hu-
man interleukin-6 receptor inhibits the development of col-
lagen arthritis in cynomolgus monkeys. Clin. Immunol. 98:
319–326.
34. Atsumi, T., K. Ishihara, D. Kamimura, H. Ikushima, T.
Ohtani, S. Hirota, H. Kobayashi, S.J. Park, Y. Saeki, Y. Kita-
mura, and T. Hirano. 2002. A point mutation of Tyr-759 in
interleukin 6 family cytokine receptor subunit gp130 causes
autoimmune arthritis. J. Exp. Med. 196:979–990.
35. Fauteux, L.J., and D.G. Osmond. 1996. IL-1 as systemic
modifier of B lymphopoiesis. Recombinant IL-1 alpha binds
to stromal cells and sinusoid endothelium in bone marrow
and precursor B cell dynamics. J. Immunol. 156:2376–2383.
36. Lin, Q., C. Dong, and M.D. Cooper. 1998. Impairment of T
and B cell development by treatment with a type I interferon.
J. Exp. Med. 187:79–87.
37. Dybedal, I., D. Bryder, A. Fossum, L.S. Rusten, and S.E. Ja-
cobsen. 2001. Tumor necrosis factor (TNF)-mediated activa-
tion of the p55 TNF receptor negatively regulates mainte-
nance of cycling reconstituting human hematopoietic stem
cells. Blood. 98:1782–1791.
38. Tang, J., B.L. Nuccie, I. Ritterman, J.L. Liesveld, C.N. Ab-
boud, and D.H. Ryan. 1997. TGF-beta down-regulates stro-
mal IL-7 secretion and inhibits proliferation of human B cell
precursors. J. Immunol. 159:117–125.
39. Wagner, U., S. Kaltenhauser, M. Pierer, B. Wilke, S. Arnold,
and H. Hantzschel. 2002. B lymphocytopenia in rheumatoid
arthritis is associated with the DRB1 shared epitope and in-
creased acute phase response. Arthritis Res. 4:R1.
40. Erkeller-Yusel, F., F. Hulstaart, I. Hannet, D. Isenberg, and
P. Lydyard. 1993. Lymphocyte subsets in a large cohort of
patients with systemic lupus erythematosus. Lupus. 2:227–
231.
41. Utsinger, P.D., and W.J. Yount. 1976. Lymphopenia in
Sjogren’s syndrome with rheumatoid arthritis: relationship to
lymphocytotoxic antibodies, cryoglobulinemia, and impaired
mitogen responsiveness. J. Rheumatol. 3:355–366.
42. Duperray, C., R. Bataille, J.M. Boiron, I.A. Haagen, J.F.
Cantaloube, X.G. Zhang, C. Boucheix, and B. Klein. 1991.
No expansion of the pre-B and B-cell compartments in the
bone marrow of patients with multiple myeloma. Cancer Res.
51:3224–3228.
43. Rawstron, A.C., F.E. Davies, R.G. Owen, A. English, G.IL-6 Production by SHIP /  Myeloid Cells Suppresses Lymphoid Development 254
Pratt, J.A. Child, A.S. Jack, and G.J. Morgan. 1998. B-lym-
phocyte suppression in multiple myeloma is a reversible phe-
nomenon specific to normal B-cell progenitors and plasma
cell precursors. Br. J. Haematol. 100:176–183.
44. Commes, T., B. Klein, M. Jourdan, G. Clofent, F. Houssiau,
J. Grenier, and R. Bataille. 1989. The defect in peripheral
blood B-cell activation in patients with multiple myeloma is
not due to a deficiency in the production of B-cell growth
and differentiation factors. J. Clin. Immunol. 9:65–73.
45. Storek, J., D. Wells, M.A. Dawson, B. Storer, and D.G. Ma-
loney. 2001. Factors influencing B lymphopoiesis after allo-
geneic hematopoietic cell transplantation. Blood. 98:489–491.
46. Takeshita, S., N. Namba, J.J. Zhao, Y. Jiang, H.K. Genant,
M.J. Silva, M.D. Brodt, C.D. Helgason, J. Kalesnikoff, M.J.
Rauh, et al. 2002. SHIP-deficient mice are severely os-
teoporotic due to increased numbers of hyper-resorptive os-
teoclasts. Nat. Med. 8:943–949.
47. Kalesnikoff, J., N. Baur, M. Leitges, M.R. Hughes, J.E. Da-
men, M. Huber, and G. Krystal. 2002. SHIP negatively regu-
lates IgE  antigen-induced IL-6 production in mast cells by
inhibiting NF-kappa B activity. J. Immunol. 168:4737–4746.
48. Tridandapani, S., Y. Wang, C.B. Marsh, and C.L. Anderson.
2002. Src homology 2 domain-containing inositol polyphos-
phate phosphatase regulates NF-kappa B-mediated gene tran-
scription by phagocytic Fc gamma Rs in human myeloid
cells. J. Immunol. 169:4370–4378.
49. Suzuki, H., Y. Terauchi, M. Fujiwara, S. Aizawa, Y. Yazaki,
T. Kadowaki, and S. Koyasu. 1999. Xid-like immunodefi-
ciency in mice with disruption of the p85alpha subunit of
phosphoinositide 3-kinase. Science. 283:390–392.
50. Fruman, D.A., S.B. Snapper, C.M. Yballe, L. Davidson, J.Y.
Yu, F.W. Alt, and L.C. Cantley. 1999. Impaired B cell de-
velopment and proliferation in absence of phosphoinositide
3-kinase p85alpha. Science. 283:393–397.